Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02223598

A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies — CLC-102  

Relapsed and Refractory Multiple Myeloma Clinical Trial

Official title:
A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, dose limiting toxicities, and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02223598
Study type Interventional
Source Cleave Biosciences, Inc.
Contact
Status Terminated
Phase Phase 1
Start date August 25, 2014
Completion date July 26, 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06050512 - Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00932698 - Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma Phase 1
Terminated NCT03683277 - IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic Phase 2
Recruiting NCT04155749 - Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma Phase 1
Completed NCT03029234 - Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma Phase 3
Recruiting NCT05530421 - Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Phase 2
Not yet recruiting NCT03559764 - Study of BCMA CAR-T in Multiple Myeloma Early Phase 1
Completed NCT02144038 - Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma Phase 1
Terminated NCT00664378 - Efficacy Study of CYT997 in Multiple Myeloma Phase 2
Terminated NCT03710915 - A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma Phase 1
Completed NCT03477643 - Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
Recruiting NCT03661554 - BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma Early Phase 1